Skip to content

Released Nov 13, 2025, after the close

10-Q filed Nov 13, 2025, 44 days after period end · 0001683168-25-008323

Q3 2025 · 10-Q
Revenue—
Net Income-$5.41MN/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.25N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$5,472,378N/M
Operating Cash Flowderived-$6,677,709N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2025Q3 2024Q3 2023
Net Income-$5.41M-$5.97M-$6.34M
EPS Diluted-$0.25-$0.55-$4.31

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR